---
title: "Durect (DRRX.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/DRRX.US.md"
symbol: "DRRX.US"
name: "Durect"
industry: "Pharmaceuticals"
---

# Durect (DRRX.US)

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |

## Company Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company’s lead product candidate includes larsucosterol, an endogenous, orally bioavailable small molecule to play a regulatory role in lipid metabolism, stress and inflammatory respons...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-19T04:30:15.000Z

**Overall: D (0.64)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 182 / 189 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 511.17% |  |
| Net Profit YoY | 77.99% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 0.00 |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 1.66M |  |


**Multi Score**: D

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -307.39% | E |
| Profit Margin | -209.90% | E |
| Gross Margin | -164.65% | E |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 511.17% | A |
| Net Profit YoY | 77.99% | A |
| Total Assets YoY | -58.19% | E |
| Net Assets YoY | -30.85% | E |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -47.64% | D |
| OCF YoY | 511.17% | A |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.08 | E |

#### Debt Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 72.10% | D |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Durect",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-307.39%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-209.90%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-164.65%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "511.17%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "77.99%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-58.19%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-30.85%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-47.64%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "511.17%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.08",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "D",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "72.10%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Eli Lilly (US.LLY) | A | A | B | E | B | B |
| 02 | ROCHE HOLDINGS AG (US.RHHVF) | A | B | B | D | C | B |
| 03 | Roche (US.RHHBY) | A | B | B | D | C | B |
| 04 | AstraZeneca (US.AZN) | A | B | C | D | C | B |
| 05 | NOVARTIS AG (US.NVS) | A | B | C | D | C | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -17.05 | 207/257 | - | - | - |
| PB | 17.03 | 182/257 | 17.03 | 17.03 | 3.28 |
| PS (TTM) | 35.80 | 142/257 | 35.80 | 35.61 | 9.48 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.91 |
| Highest Target | 2.50 |
| Lowest Target | 2.50 |

## References

- [Company Overview](https://longbridge.com/en/quote/DRRX.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/DRRX.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/DRRX.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.